東華大學圖書館 |

Omega-3 Fatty Acids in the Treatment of Childhood Cancer.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Omega-3 Fatty Acids in the Treatment of Childhood Cancer./
作者:	Ljungblad, Linda.
面頁冊數:	1 online resource (89 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-05, Section: B.
Contained By:	Dissertations Abstracts International84-05B.
標題:	Brain cancer. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30154747click for full text (PQDT)
ISBN:	9798352985496

Omega-3 Fatty Acids in the Treatment of Childhood Cancer.
Ljungblad, Linda.

Omega-3 Fatty Acids in the Treatment of Childhood Cancer. - 1 online resource (89 pages)

Source: Dissertations Abstracts International, Volume: 84-05, Section: B.

Thesis (Ph.D.)--Karolinska Institutet (Sweden), 2022.

Includes bibliographical references

Childhood cancer is the primary cause of deaths among Swedish children. Advances in treatment regimens have improved cure rate considerably in the latest decades. Consequently, childhood cancer survivors are a growing population with a significant risk of long-term side effects such as neurocognitive decline, endocrine dysfunction, risk of relapse or a second malignancy. The embryonal tumors neuroblastoma and medulloblastoma are heterogenous childhood tumors arising in the peripheral nervous system and cerebellum, respectively. While low-risk subsets of neuroblastoma and medulloblastoma have a good prognosis with survival rates above 90%, high-risk subsets have poor prognosis with survival rates below 50% despite intensified treatment.The polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibit anti-tumor and anti-inflammatory properties in various cancers including neuroblastoma. In contrast, the pro-inflammatory metabolite prostaglandin E2 (PGE2), derived from the omega-6 fatty acid arachidonic acid (AA) is known to induce inflammation and immune suppression in the tumor microenvironment. Inhibition of PGE2 formation has been identified as an attractive therapeutic approach in malignancies including medulloblastoma and neuroblastoma.This thesis is based on preclinical and clinical studies aiming to promote better treatment for children with cancer using the omega-3 fatty acids EPA and DHA and in particular investigate effects on medulloblastoma and neuroblastoma.The investigations in paper I revealed that omega-3 supplementation reduced tumor growth, PGE2 production, and CRYAB expression in preclinical models of medulloblastoma. Omega3 supplementation modulated neuroblastoma tumor microenvironment by increasing the chemoattractant CCL3 and reducing AA-derived metabolites, including PGE2. Additionally, the AA-derived metabolites correlated with the infiltration of regulatory T cells in the tumors. Available gene expression data sets indicate that low CCL3 expression is associated with high-risk subgroups, metastatic disease, and poor overall survival in neuroblastoma (paper II).Several studies of omega-3 supplementation have been performed in adults and children of various ages and size but without reaching consensus regarding appropriate dosing so far. To pave way for future clinical studies and elucidate a dosing strategy, a dose-finding study of EPA and DHA supplementation was performed (paper III). Children aged 3-16 years in clinical remission after concluded cancer therapy received EPA and DHA supplementation based on the body surface area for 90 days. No severe adverse events were observed and the participants exhibited high adherence to the supplementation regardless of dose. Our findings suggest an EPA +DHA dose of about 1500 mg/m2 body surface area for further studies based on a sufficient incorporation of EPA and DHA in erythrocytes, a decrease of the omega6:omega-3 ratios, and the observed unpredictability of fatty acid incorporation at the highest doses. While the main aim of this study was to guide dosing for future clinical trials, immunomonitoring of the patients during the supplementation was included as a secondary aim revealing an increase in activated NK cells (paper IV).In summary, this thesis provides insight into the inhibitory effect of omega-3 fatty acids on the AA-derived metabolites in medulloblastoma and neuroblastoma tumor tissue and, additionally, proposes a dosing strategy for omega-3 fatty acid supplementation for comparative studies in pediatric oncology.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798352985496Subjects--Topical Terms:

3557728
Brain cancer.
Index Terms--Genre/Form:

542853
Electronic books.

Omega-3 Fatty Acids in the Treatment of Childhood Cancer.
LDR:04978nmm a2200397K 4500 001 2365722
005 20231218204649.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798352985496
035 $a (MiAaPQ)AAI30154747
035 $a (MiAaPQ)Karolinska_1061648155
035 $a AAI30154747
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Ljungblad, Linda. $3 3706590
245 1 0 $a Omega-3 Fatty Acids in the Treatment of Childhood Cancer.
264 0 $c 2022
300 $a 1 online resource (89 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-05, Section: B.
500 $a Advisor: Kogner, Per;Wickstrom, Malin;Gleissman, Helena;Strandvik, Birgitta.
502 $a Thesis (Ph.D.)--Karolinska Institutet (Sweden), 2022.
504 $a Includes bibliographical references
520 $a Childhood cancer is the primary cause of deaths among Swedish children. Advances in treatment regimens have improved cure rate considerably in the latest decades. Consequently, childhood cancer survivors are a growing population with a significant risk of long-term side effects such as neurocognitive decline, endocrine dysfunction, risk of relapse or a second malignancy. The embryonal tumors neuroblastoma and medulloblastoma are heterogenous childhood tumors arising in the peripheral nervous system and cerebellum, respectively. While low-risk subsets of neuroblastoma and medulloblastoma have a good prognosis with survival rates above 90%, high-risk subsets have poor prognosis with survival rates below 50% despite intensified treatment.The polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibit anti-tumor and anti-inflammatory properties in various cancers including neuroblastoma. In contrast, the pro-inflammatory metabolite prostaglandin E2 (PGE2), derived from the omega-6 fatty acid arachidonic acid (AA) is known to induce inflammation and immune suppression in the tumor microenvironment. Inhibition of PGE2 formation has been identified as an attractive therapeutic approach in malignancies including medulloblastoma and neuroblastoma.This thesis is based on preclinical and clinical studies aiming to promote better treatment for children with cancer using the omega-3 fatty acids EPA and DHA and in particular investigate effects on medulloblastoma and neuroblastoma.The investigations in paper I revealed that omega-3 supplementation reduced tumor growth, PGE2 production, and CRYAB expression in preclinical models of medulloblastoma. Omega3 supplementation modulated neuroblastoma tumor microenvironment by increasing the chemoattractant CCL3 and reducing AA-derived metabolites, including PGE2. Additionally, the AA-derived metabolites correlated with the infiltration of regulatory T cells in the tumors. Available gene expression data sets indicate that low CCL3 expression is associated with high-risk subgroups, metastatic disease, and poor overall survival in neuroblastoma (paper II).Several studies of omega-3 supplementation have been performed in adults and children of various ages and size but without reaching consensus regarding appropriate dosing so far. To pave way for future clinical studies and elucidate a dosing strategy, a dose-finding study of EPA and DHA supplementation was performed (paper III). Children aged 3-16 years in clinical remission after concluded cancer therapy received EPA and DHA supplementation based on the body surface area for 90 days. No severe adverse events were observed and the participants exhibited high adherence to the supplementation regardless of dose. Our findings suggest an EPA +DHA dose of about 1500 mg/m2 body surface area for further studies based on a sufficient incorporation of EPA and DHA in erythrocytes, a decrease of the omega6:omega-3 ratios, and the observed unpredictability of fatty acid incorporation at the highest doses. While the main aim of this study was to guide dosing for future clinical trials, immunomonitoring of the patients during the supplementation was included as a secondary aim revealing an increase in activated NK cells (paper IV).In summary, this thesis provides insight into the inhibitory effect of omega-3 fatty acids on the AA-derived metabolites in medulloblastoma and neuroblastoma tumor tissue and, additionally, proposes a dosing strategy for omega-3 fatty acid supplementation for comparative studies in pediatric oncology.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Brain cancer. $3 3557728
650 4 $a Disease. $3 705846
650 4 $a Brain research. $3 3561789
650 4 $a Mutation. $3 837917
650 4 $a Fatty acids. $3 897910
650 4 $a Diet. $3 626002
650 4 $a Metabolism. $3 541349
650 4 $a Lipids. $3 558980
650 4 $a Apoptosis. $3 600650
650 4 $a Blood. $3 641576
650 4 $a Pediatrics. $3 559143
650 4 $a Breast cancer. $3 3543523
650 4 $a Angiogenesis. $3 3561733
650 4 $a Drug dosages. $3 3557732
650 4 $a Membranes. $3 1531702
650 4 $a Age. $3 1486010
650 4 $a Surgery. $3 707153
650 4 $a Nervous system. $3 672432
650 4 $a Bone marrow. $3 1621080
650 4 $a Tumors. $3 893964
650 4 $a Enzymes. $3 520899
650 4 $a Animal cognition. $3 3563972
650 4 $a Metabolites. $3 683644
650 4 $a Multiple myeloma. $3 864788
650 4 $a Adults. $3 2157228
650 4 $a Behavioral sciences. $3 529833
650 4 $a Cellular biology. $3 3172791
650 4 $a Medicine. $3 641104
650 4 $a Morphology. $3 591167
650 4 $a Neurosciences. $3 588700
650 4 $a Oncology. $3 751006
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0576
690 $a 0602
690 $a 0379
690 $a 0564
690 $a 0287
690 $a 0317
690 $a 0992
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Karolinska Institutet (Sweden). $3 3557748
773 0 $t Dissertations Abstracts International $g 84-05B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30154747 $z click for full text (PQDT)